Spoke Chooses T IoT from T-Mobile and Deutsche Telekom to Pave the Way for Safer Cycling
13.7.2022 17:34:00 EEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) and Deutsche Telekom (NASDAQ: DTEGY) announced that Spoke, a mobility platform for safety, connectivity and rich rider experiences, will use T IoT to help bicyclists and motorists share the road more safely. T IoT, a comprehensive solution for global IoT connectivity, platform management and support, will power Spoke’s new hardware and software system that delivers near real-time information to bicyclists and motorists on the road, to help them reach their destination safely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712006196/en/
With T IoT, Spoke aims to improve awareness between bicyclists and motorists worldwide (Graphic: Business Wire)
According to the National Highway Traffic Safety Administration, 78 percent of bicycle accidents happen in urban areas where bicyclists ride near traffic. Spoke is on a journey to shrink those numbers by creating an ecosystem of IoT-connected sensors and cameras to provide bicyclists and motorists with highly accurate and timely alerts that will be delivered over LTE and 5G. This helps ensure that bicycles can “digitally” see cars, and more importantly, that cars can see bicycles.
Consider that there were nearly 50 million bicycles sold last year across the world. Then think about the millions of connected vehicles on roadways across the globe. Right now, the process of connecting vehicles to data requires the time-consuming, cumbersome process of enterprise negotiations with different network operators and IoT platforms. And bicyclists and motorists obviously don’t care how a safety notification is delivered or which jurisdiction they are in, as long as alerts are timely and actionable — because the outcome can oftentimes prevent property damage, injury, or ultimately save a life.
T IoT delivers network connectivity spanning the full range of technologies to support nearly every possible IoT scenario today, and tomorrow — including NB-IoT, LTE-M, LTE, and 5G — making it optimized to help deliver near real-time connectivity at scale, in 188 destinations worldwide.
“T IoT supports the low-latency speed and massive data required to connect Spoke’s global network of hardware and software on the road,” said Jarrett Wendt, CEO, Spoke. “As a result, Spoke will deliver much more than peace of mind for cyclists. It will deliver a world-class user experience with ride-enriching features made just for them — like traffic, navigation, ride and health information. T-Mobile and Deutsche Telekom’s leading innovation makes them the perfect teammate for Spoke’s solutions.”
“Spoke is exactly the kind of customer, innovation, and global application we had in mind when we launched T IoT earlier this year,” said Mishka Dehghan, Senior Vice President, Strategy, Product, and Solutions Engineering, T-Mobile Business Group. “Spoke is looking to leverage IoT and 5G for global good, and with T IoT, they will have one team and solution to manage all their connections around the world — to help the most vulnerable on our roadways by connecting them to the mobility ecosystem around them.”
“The future of our traffic system is based on a robust vehicle-to-everything (C-V2X) ecosystem provided through global cellular 5G connectivity. We are happy to support pioneers like Spoke and help building up a reliable connected system for mobility safety and rich rider experiences through our T IoT global footprint”, said Dennis Nikles, CEO of Deutsche Telekom IoT.
To learn more about T IoT from T-Mobile and Deutsche Telekom, go to: www.t-mobile.com/business/solutions/iot/T IoT-global
For more information about Spoke, visit: www.spokesafety.com
Qualifying service & devices required. Coverage not available in some areas.
About T-Mobile
T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712006196/en/
Contact information
Media Contacts
T-Mobile US, Inc. Media Relations
MediaRelations@t-mobile.com
Investor Relations Contact
T-Mobile US, Inc.
investor.relations@t-mobile.com
https://investor.t-mobile.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom